Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age
about
An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.Non-clinical safety and biodistribution of AS03-adjuvanted inactivated pandemic influenza vaccines.Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older.Clinical Expectations for Better Influenza Virus Vaccines-Perspectives from the Young Investigators' Point of ViewAdjuvanted influenza vaccines
P2860
Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Assessment of squalene adjuvan ...... en 6 months to 17 years of age
@ast
Assessment of squalene adjuvan ...... en 6 months to 17 years of age
@en
type
label
Assessment of squalene adjuvan ...... en 6 months to 17 years of age
@ast
Assessment of squalene adjuvan ...... en 6 months to 17 years of age
@en
prefLabel
Assessment of squalene adjuvan ...... en 6 months to 17 years of age
@ast
Assessment of squalene adjuvan ...... en 6 months to 17 years of age
@en
P2093
P2860
P356
P1476
Assessment of squalene adjuvan ...... en 6 months to 17 years of age
@en
P2093
Agnès Hoffenbach
Inca Kusters
Martine Denis
Stéphanie Pepin
Timo Vesikari
P2860
P304
P356
10.4161/HV.21265
P577
2012-08-21T00:00:00Z